GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lobe Sciences Ltd (OTCPK:LOBEF) » Definitions » Net Income Including Noncontrolling Interests

LOBEF (Lobe Sciences) Net Income Including Noncontrolling Interests : $-3.45 Mil (TTM As of Feb. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Lobe Sciences Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Lobe Sciences's Net Income Including Noncontrolling Interests for the three months ended in Feb. 2025 was $-0.49 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Feb. 2025 was $-3.45 Mil.


Lobe Sciences Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Lobe Sciences's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lobe Sciences Net Income Including Noncontrolling Interests Chart

Lobe Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.60 -7.67 -9.49 -3.49 -3.24

Lobe Sciences Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.44 -0.31 -2.07 -0.57 -0.49

Lobe Sciences Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lobe Sciences Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Lobe Sciences's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.


Lobe Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lobe Sciences Ltd (OTCPK:LOBEF) » Definitions » Net Income Including Noncontrolling Interests
Traded in Other Exchanges
Address
1771 Robson Street, No. 1614, Vancouver, BC, CAN, V6G 3B7
Lobe Sciences Ltd is a biopharmaceutical company committed to discovering and developing patient-focused medicines for orphan and rare diseases. It is engaged in drug research and development to improve brain and mental health and wellness. The company plans to commercialize a medical food named Altemia for the treatment of Sickle Cell Disease and has other drugs in pipeline such as L-130 Treatment for Chronic Cluster Headache, L-131 Treatment for Pediatric Anxiety and S-100 Treatment for Sickle Cell Disease.